INVESTIGADORES
MARTIN Gabriela Adriana
congresos y reuniones científicas
Título:
Antitumoral effects of rosiglitazone are independent of PPAR gamma in NMU-induced tumors
Autor/es:
NÚÑEZ M, GUTIÉRREZ A, COCCA C, MEDINA V, CROCI M, RIVERA E, MARTÍN G, BERGOC R
Lugar:
San Miguel de Tucuman, Argentina
Reunión:
Congreso; XLV Reunión Anual Sociedad Argentina de Investigación en Bioquímica y Biología Molecular; 2009
Institución organizadora:
Sociedad Argentina de Investigación en Bioquímica y Biología Molecular
Resumen:
The thiazolidinediones such as Rosiglitazone (R) are antidiabetic
agents acting through the activation of peroxisome proliferatoractivated
receptor gamma (PPARg). PPARg ligands have recently
been identified as potential targets for the treatment of human
cancers including breast cancer. We have previously reported that R
inhibits the tumor growth rate of mammary tumors induced in rats
through the ip administration of N-Nitroso-N-methylurea (NMU).
The aim of the present work was to investigate the expression of
PPARg and proliferation markers in mammary normal tissue and
NMU-induced tumors of untreated and R-treated (0.06 mg/Kg/day)
rats. The percentage expression of PPARg and proliferating cell
n u c l e a r a n t i g e n ( P C N A ) w a s d e t e rmi n e d b y
immunohistochemistry. The PPARg expression was scarce in
mammary tumors while it was significantly higher in normal
mammary tissue (p<0.001). PPARg immunoreactivity was
observed preferentially in the nucleus of ductal epithelial cells. On
the other hand, PCNA expression was low in normal mammary
tissue while it was higher in mammary tumors (p<0.001). In
addition, R treatment significantly reduced PCNA (p<0.0001)
while did not modify PPARg tumor expression. On the basis of the
present results, we conclude that PPARg expression decreases
during carcinogenesis and that the R antitumoral effects are
independent of PPARg in this experimental model.